Rheumatoid arthritis market in Asia-Pacific to reach $7 billion by 2021

3 June 2015

The rheumatoid arthritis (RA) therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate compound annual growth rate (CAGR) of 3.3%, new research finds.

According to business intelligence provider GBI Research’s latest report, the four major APAC countries, namely Australia, China, India and Japan, the latter will retain the largest share, with its market value expanding from about $4.1 billion in 2014 to $4.7 billion by 2021.

Sumith Ladda, an analyst for GBI Research, says the entry of new therapies over the forecast period will stimulate market growth, with promising pipeline candidates including Eli Lilly (NYSE: LLY) and Incyte’s (Nasdaq: INCY) baricitinib, Johnson & Johnson (NYSE: JNJ) and GlaxoSmithKline’s (LSE: GSK) sirukumab, and Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) sarilumab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK